
The AIDS Foundation of Chicago (AFC) and Project PrEPare recently hosted a community forum to discuss next steps after a study showed an HIV drug could prevent infection in healthy gay men.
AFC Director of Advocacy Jim Pickett and Keith Green, director for Project PrEPare, a Chicago-based component of the international iPrEx study, moderated the discussion of potential risks and benefits of pre-exposure prophylaxis (PrEP). The study of men who have sex with men (MSM) and transgender persons who have sex with men found those who received daily emtricitabine plus tenofovir (Truvada) -- and also condoms, counseling, and other prevention services -- saw their infection risk cut by 43.8 percent. Participants with even better drug adherence realized more protection, up to 72.8 percent.
Dr. Sybil Hosek, a principal investigator for Project PrEPare, noted iPrEx is the first study of its kind. "The folks at iPrEx recognize that there is still a lot that needs to be understood," she said.
[...]
Complete article at The Body : http://bit.ly/i7QVHn

Illinois: Project PrEPare, AIDS Foundation of Chicago Hold HIV Drug Forum (TheBody)

